VistaGen Therapeutics(US:VTGN) Globenewswire·2026-02-26 14:18Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [4][6]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a company listed on NASDAQ under the ticker VTGN [4]. - The company is developing fasedienol, an investigational pherine candidate aimed at treating social anxiety disorder [6]. Group 2: Legal Investigation - The law firm Faruqi & Faruqi is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [4][8]. Group 3: Trial Results and Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, reporting no statistically significant improvement in anxiety reduction compared to placebo [7]. - Following the announcement, Vistagen's stock price fell by $3.50, or 80.27%, closing at $0.86 [7]. Group 4: Investor Communication - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [9].